Marketdash
Back to News

Top-Rated Wall Street Analysts Spotlight 3 Healthcare Dividend Stocks Worth Watching

MarketDash Editorial Team
7 days ago
When markets get choppy, dividend stocks become investor favorites. Here's what Wall Street's most accurate analysts are saying about three healthcare companies offering yields between 3.31% and 5.04%, complete with recent price target updates and company developments.

When the market gets turbulent, investors often reach for the financial equivalent of a comfort blanket: dividend-yielding stocks. These companies typically generate substantial free cash flows and share the wealth with shareholders through regular dividend payouts. It's a strategy that feels particularly appealing when growth stocks are doing their roller-coaster impression.

Here's what some of Wall Street's most accurate analysts are saying about three healthcare sector stocks that are currently delivering attractive dividend yields. And we're not just talking about any analysts here—these are the ones with track records that actually hold up under scrutiny.

CVS Health Corp (CVS)

Dividend Yield: 3.31%

CVS Health has caught the attention of two prominent analysts recently, and both came away impressed enough to raise their price targets. Truist Securities analyst David Macdonald maintained a Buy rating on October 30, 2025, and bumped his price target from $92 to $95. With an accuracy rate of 69%, Macdonald's track record suggests his calls are worth paying attention to.

Not to be outdone, Morgan Stanley analyst Erin Wright maintained an Overweight rating on October 14, 2025, and boosted the price target from $82 to $89. Wright's accuracy rate of 75% is particularly noteworthy—that's the kind of batting average that gets you noticed on Wall Street.

In recent company news, CVS Health named David Joyner Chair of the board of directors on November 20. It's a leadership move that signals the company's ongoing efforts to navigate the complex healthcare landscape.

Viatris Inc (VTRS)

Dividend Yield: 4.49%

Viatris is serving up the middle yield in this trio, and it's attracted some fresh analyst coverage. Truist Securities analyst Srikripa Devarakonda initiated coverage on October 15, 2025, with a Buy rating and a price target of $15. Devarakonda's accuracy rate of 67% suggests a solid track record of getting calls right.

Meanwhile, Goldman Sachs analyst Matt Dellatorre took a more measured approach when initiating coverage on June 6, 2025, with a Neutral rating and a $10 price target. Dellatorre's 69% accuracy rate means his cautious stance carries weight—when someone with that kind of track record says "neutral," it's worth understanding why.

On the fundamental side, Viatris posted upbeat earnings for the third quarter on November 6, suggesting the business is executing well even as analysts debate the stock's upside potential.

Bristol-Myers Squibb Co (BMY)

Dividend Yield: 5.04%

Bristol-Myers Squibb takes the crown for highest dividend yield in this group at just over 5%. But here's where things get interesting—recent analyst moves have been more about trimming expectations than raising them.

Citigroup analyst Andrew Baum maintained a Neutral rating on November 17, 2025, but cut the price target from $48 to $45. With an accuracy rate of 72%, Baum's price target reduction is worth noting, even if he's not turning negative on the stock outright.

Wells Fargo analyst Mohit Bansal also maintained an Equal-Weight rating but slashed the price target from $62 to $53 back on April 28, 2025. Bansal's 71% accuracy rate suggests this wasn't just a throwaway call—there were legitimate concerns about valuation at higher levels.

That said, Bristol-Myers Squibb continues to advance its pipeline. On November 24, the company disclosed that it received approval from the European Commission to expand the use of its CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma. It's the kind of regulatory win that can drive long-term value, even if analysts are being cautious about near-term stock performance.

The Bottom Line on Dividend Healthcare Plays

What ties these three stocks together isn't just their dividend yields—it's that they're all established healthcare companies with the kind of cash-generating businesses that can sustain those payouts. When markets get choppy, that sustainability matters more than the absolute yield percentage.

The analyst ratings tell an interesting story too. CVS is getting bullish upgrades, Viatris is attracting mixed signals with new coverage, and Bristol-Myers Squibb is seeing price target cuts despite maintaining its dividend. That's the real world of dividend investing—not every high-yielding stock is on the same trajectory, and that's exactly why tracking what accurate analysts are saying matters.

For investors looking to add dividend exposure in healthcare, these three stocks represent different risk-reward profiles, all backed by analysts who have demonstrated they know what they're doing. Whether you're drawn to the relative safety of a 3.31% yield or willing to accept the questions that come with a 5.04% payout, understanding what Wall Street's best analysts are thinking gives you a crucial edge.

Back to News

Top-Rated Wall Street Analysts Spotlight 3 Healthcare Dividend Stocks Worth Watching

MarketDash Editorial Team
7 days ago
When markets get choppy, dividend stocks become investor favorites. Here's what Wall Street's most accurate analysts are saying about three healthcare companies offering yields between 3.31% and 5.04%, complete with recent price target updates and company developments.

When the market gets turbulent, investors often reach for the financial equivalent of a comfort blanket: dividend-yielding stocks. These companies typically generate substantial free cash flows and share the wealth with shareholders through regular dividend payouts. It's a strategy that feels particularly appealing when growth stocks are doing their roller-coaster impression.

Here's what some of Wall Street's most accurate analysts are saying about three healthcare sector stocks that are currently delivering attractive dividend yields. And we're not just talking about any analysts here—these are the ones with track records that actually hold up under scrutiny.

CVS Health Corp (CVS)

Dividend Yield: 3.31%

CVS Health has caught the attention of two prominent analysts recently, and both came away impressed enough to raise their price targets. Truist Securities analyst David Macdonald maintained a Buy rating on October 30, 2025, and bumped his price target from $92 to $95. With an accuracy rate of 69%, Macdonald's track record suggests his calls are worth paying attention to.

Not to be outdone, Morgan Stanley analyst Erin Wright maintained an Overweight rating on October 14, 2025, and boosted the price target from $82 to $89. Wright's accuracy rate of 75% is particularly noteworthy—that's the kind of batting average that gets you noticed on Wall Street.

In recent company news, CVS Health named David Joyner Chair of the board of directors on November 20. It's a leadership move that signals the company's ongoing efforts to navigate the complex healthcare landscape.

Viatris Inc (VTRS)

Dividend Yield: 4.49%

Viatris is serving up the middle yield in this trio, and it's attracted some fresh analyst coverage. Truist Securities analyst Srikripa Devarakonda initiated coverage on October 15, 2025, with a Buy rating and a price target of $15. Devarakonda's accuracy rate of 67% suggests a solid track record of getting calls right.

Meanwhile, Goldman Sachs analyst Matt Dellatorre took a more measured approach when initiating coverage on June 6, 2025, with a Neutral rating and a $10 price target. Dellatorre's 69% accuracy rate means his cautious stance carries weight—when someone with that kind of track record says "neutral," it's worth understanding why.

On the fundamental side, Viatris posted upbeat earnings for the third quarter on November 6, suggesting the business is executing well even as analysts debate the stock's upside potential.

Bristol-Myers Squibb Co (BMY)

Dividend Yield: 5.04%

Bristol-Myers Squibb takes the crown for highest dividend yield in this group at just over 5%. But here's where things get interesting—recent analyst moves have been more about trimming expectations than raising them.

Citigroup analyst Andrew Baum maintained a Neutral rating on November 17, 2025, but cut the price target from $48 to $45. With an accuracy rate of 72%, Baum's price target reduction is worth noting, even if he's not turning negative on the stock outright.

Wells Fargo analyst Mohit Bansal also maintained an Equal-Weight rating but slashed the price target from $62 to $53 back on April 28, 2025. Bansal's 71% accuracy rate suggests this wasn't just a throwaway call—there were legitimate concerns about valuation at higher levels.

That said, Bristol-Myers Squibb continues to advance its pipeline. On November 24, the company disclosed that it received approval from the European Commission to expand the use of its CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma. It's the kind of regulatory win that can drive long-term value, even if analysts are being cautious about near-term stock performance.

The Bottom Line on Dividend Healthcare Plays

What ties these three stocks together isn't just their dividend yields—it's that they're all established healthcare companies with the kind of cash-generating businesses that can sustain those payouts. When markets get choppy, that sustainability matters more than the absolute yield percentage.

The analyst ratings tell an interesting story too. CVS is getting bullish upgrades, Viatris is attracting mixed signals with new coverage, and Bristol-Myers Squibb is seeing price target cuts despite maintaining its dividend. That's the real world of dividend investing—not every high-yielding stock is on the same trajectory, and that's exactly why tracking what accurate analysts are saying matters.

For investors looking to add dividend exposure in healthcare, these three stocks represent different risk-reward profiles, all backed by analysts who have demonstrated they know what they're doing. Whether you're drawn to the relative safety of a 3.31% yield or willing to accept the questions that come with a 5.04% payout, understanding what Wall Street's best analysts are thinking gives you a crucial edge.